Kelvin L Chou1, Adrienne Lenhart2, Robert A Koeppe3, Nicolaas I Bohnen4. 1. Department of Neurology, University of Michigan, Ann Arbor, MI, USA. 2. Wayne State University School of Medicine, Detroit, MI, USA. 3. Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, USA. 4. Department of Neurology, University of Michigan, Ann Arbor, MI, USA; Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, USA; Neurology Service and GRECC, VAAAHS, Ann Arbor, MI, USA. Electronic address: klchou@med.umich.edu.
Abstract
BACKGROUND: The Montreal Cognitive Assessment (MoCA) is increasingly being used as a cognitive screening test in Parkinson disease (PD). The MoCA's popularity likely reflects its ability to detect executive dysfunction, a relative deficiency of the Mini-Mental State Examination (MMSE). OBJECTIVE: To compare neurochemical and neuropsychological functions in non-demented PD patients with mild cognitive impairment (PD-MCI) and without, as defined by MoCA (PD-MCI = MoCA<26). METHODS: Non-demented PD subjects underwent combined MoCA and MMSE, detailed cognitive testing and [¹¹C]methyl-4-piperidinyl propionate acetylcholinesterase and [¹¹C]dihydrotetrabenazine monoaminergic PET imaging. RESULTS: Eighteen subjects met MoCA PD-MCI criteria but had MMSE scores in the normal range, compared to 29 subjects with normal MoCA and MMSE scores. The MoCA-defined PD-MCI group had reduced performance in global cognition (t = 2.91, P = 0.0056), most significantly in executive function (t = 3.18, P = 0.002), as well as significant reduction in dorsal caudate nucleus dopaminergic innervation (t = 2.72, P = 0.009) compared to the PD without MCI group. Both MoCA and MMSE had poor diagnostic accuracy for PD-MCI (65.3%) when using the Level 2 Movement Disorder Society Task Force definition. CONCLUSION: PD subjects with normal range MMSE but abnormal MoCA scores had evidence of caudate nucleus dopaminergic denervation and mild cognitive changes, predominantly in executive function. The MoCA may be able to preferentially detect executive dysfunction compared to the MMSE, but the MoCA has limited diagnostic accuracy for PD-MCI, and should not be used alone to make this diagnosis.
BACKGROUND: The Montreal Cognitive Assessment (MoCA) is increasingly being used as a cognitive screening test in Parkinson disease (PD). The MoCA's popularity likely reflects its ability to detect executive dysfunction, a relative deficiency of the Mini-Mental State Examination (MMSE). OBJECTIVE: To compare neurochemical and neuropsychological functions in non-demented PD patients with mild cognitive impairment (PD-MCI) and without, as defined by MoCA (PD-MCI = MoCA<26). METHODS: Non-demented PD subjects underwent combined MoCA and MMSE, detailed cognitive testing and [¹¹C]methyl-4-piperidinyl propionate acetylcholinesterase and [¹¹C]dihydrotetrabenazine monoaminergic PET imaging. RESULTS: Eighteen subjects met MoCAPD-MCI criteria but had MMSE scores in the normal range, compared to 29 subjects with normal MoCA and MMSE scores. The MoCA-defined PD-MCI group had reduced performance in global cognition (t = 2.91, P = 0.0056), most significantly in executive function (t = 3.18, P = 0.002), as well as significant reduction in dorsal caudate nucleus dopaminergic innervation (t = 2.72, P = 0.009) compared to the PD without MCI group. Both MoCA and MMSE had poor diagnostic accuracy for PD-MCI (65.3%) when using the Level 2 Movement Disorder Society Task Force definition. CONCLUSION: PD subjects with normal range MMSE but abnormal MoCA scores had evidence of caudate nucleus dopaminergic denervation and mild cognitive changes, predominantly in executive function. The MoCA may be able to preferentially detect executive dysfunction compared to the MMSE, but the MoCA has limited diagnostic accuracy for PD-MCI, and should not be used alone to make this diagnosis.
Authors: S Nagatsuka Si; K Fukushi; H Shinotoh; H Namba; M Iyo; N Tanaka; A Aotsuka; T Ota; S Tanada; T Irie Journal: J Cereb Blood Flow Metab Date: 2001-11 Impact factor: 6.200
Authors: Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky Journal: Arch Neurol Date: 2003-12
Authors: Erika A Pugh; Emily C Kemp; Christopher H van Dyck; Adam P Mecca; Emily S Sharp Journal: Am J Geriatr Psychiatry Date: 2018-09-21 Impact factor: 4.105
Authors: Roberta Biundo; L Weis; S Bostantjopoulou; E Stefanova; C Falup-Pecurariu; M G Kramberger; G J Geurtsen; A Antonini; D Weintraub; D Aarsland Journal: J Neural Transm (Vienna) Date: 2016-02-06 Impact factor: 3.575
Authors: Taylor Chomiak; Fernando Vieira Pereira; Nicole Meyer; Natalie de Bruin; Lorelei Derwent; Kailie Luan; Alexandra Cihal; Lesley A Brown; Bin Hu Journal: J Neural Transm (Vienna) Date: 2015-07-24 Impact factor: 3.575
Authors: Jeffrey L B Bohnen; Martijn L T M Müller; Jacob Haugen; Nicolaas I Bohnen Journal: J Neural Transm (Vienna) Date: 2017-07-19 Impact factor: 3.575